Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that it
is scheduled to present this week at the Jefferies Second Annual
Healthcare Conference on Wednesday, June 25, 2008, at 2:30 p.m. (EDT) in
New York City. The event will be webcast live and will be available on
the Company’s website or by visiting http://www.wsw.com/webcast/jeff26/abpi.
An archived edition of the presentation will be available following the
event.
Based on imminent reports of milestones expected from Accentia’s
majority owned subsidiary, Biovest International, Inc. (OTCBB:BVTI),
Steven Arikian, M.D. will focus his presentation on BiovaxID®,
Biovest’s anti-cancer vaccine targeting
non-Hodgkin’s lymphoma. Dr. Arikian serves as
President and Chief Operating Officer, Biopharmaceutical Products &
Services, of Accentia and as Chairman and CEO of Biovest.
If qualified investors are interested in meeting with Dr. Arikian at the
Jefferies Healthcare Conference, please contact Douglas Calder at
813-864-2558 or at dwcalder@accentia.net.
About Accentia Biopharmaceuticals, Inc.
Accentia Biopharmaceuticals, Inc. (Nasdaq:ABPI) is committed to building
significant value for its stockholders through the commercialization of
patent-protected disruptive healthcare technologies designed to be
positioned as leading products for the treatment of a broad range of
chronic, debilitating and life-threatening diseases including
respiratory, autoimmune and cancer indications. The Company generated
more than $18 million in revenues in fiscal-year 2007, primarily based
on sales of its marketed specialty pharmaceutical products and its
analytical consulting business serving biopharmaceutical clients.
Accentia is advancing a portfolio of potential blockbuster drug
candidates which target multi-billion dollar market opportunities. These
late-stage products include: BiovaxID®,
a novel anti-idiotype cancer vaccine for the treatment of B-cell
malignancies including indolent follicular non-Hodgkin’s
lymphoma; Revimmune™, a novel
ultra-high-dose formulation of a previously approved chemotherapeutic
agent expected to show utility in the treatment of up to 80 autoimmune
diseases, with an initial focus on multiple sclerosis; and SinuNase™,
a novel formulation of a previously approved anti-fungal for the
topical, intranasal treatment of chronic sinusitis.
Accentia’s interest in BiovaxID is based on
its majority ownership stake in Biovest International, Inc.
(OTCBB:BVTI), and Accentia also maintains a royalty interest in Biovest’s
biologic products.
